Longeveron Inc - Ordinary Shares - Class A
LGVN
Get informed when a big investor buys or sells
+ FollowMarket Cap$20.45M
Close$
$-0.23
103.5% downside
Current Fair Value
103.5% downsideOvervalued by 103.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $20.45 Million |
|---|---|
| Enterprise Value | $10.99 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-12.9 |
| Beta | -0.25 |
| Outstanding Shares | 3,137,763 |
Return
| Return on Equity | -225.67% |
|---|---|
| Return on Assets | -151.57% |
| Return on Invested Capital | -212.46% |
Valuation & Multiples
| P/E Ratio | -0.67 |
|---|---|
| PEG | -3.2 |
| Price to Sales | - |
| Price to Book Ratio | 2.19 |
| Enterprise Value to Revenue | 9.26 |
| Enterprise Value to EBIT | -0.46 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.06 |
| Debt to Equity | 0.06 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 12, 2026
EPS Estimate
$-1.75
Average shareholder expectationRevenue Estimate
$326,000
Average shareholder expectationNext Earnings Call
Expected Date
November 3, 2026
EPS Estimate
$-1.63
Average shareholder expectationRevenue Estimate
$400,000
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 9.19%▲ 4.73% |
|---|---|
| Total Invested | $2.37M▲ 355.07% |
| Investors Holding | 30▲ 1.00% |
ESG Score
No data
About Longeveron Inc
26 employeeslongeveron llc is a leading global regenerative medicine company developing innovative cellular therapeutics for chronic life-threatening diseases. our lead investigational product candidate (lmsc) is based on a specialized cell known as...